Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

KMT2A -Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Venkata Sesha Sai Abhinav Ayyadevara, Gerald Wertheim, John Chukinas, Joseph Loftus, Sung June Lee, Anil Kumar, Srividya Swaminathan, Rahul S Bhansali, Wayne Childers, Huimin Geng, Thomas A Milne, Xianxin Hua, Kathrin M. Bernt, Thierry Besson, Junwei Shi, John D. Crispino, Martin P Carroll, Sarah K. Tasian, Christian Hurtz

Blood (2024) 144 (Supplement 1): 1455.

https://doi.org/10.1182/blood-2024-206134

Published: 2024

Journal Articles

Targeting the SWI/SNF Chromatin Remodeling Complex Subunit SMARCA4 in ALL

Venkata Sesha Sai Abhinav Ayyadevara, Ashley Paik, Ria Perencsik, Monika Toma, Tomasz Skorski, Rozbeh Jafari, Gerald Wertheim, Huimin Geng, Christian Hurtz

Blood (2024) 144 (Supplement 1): 4216.

https://doi.org/10.1182/blood-2024-205936

Published: 2024

Journal Articles

Immunoglobulin Light Chains Control Permissiveness to Malignant B-Cell Transformation By RAS-Pathway Lesions

Lai N Chan, Kohei Kume, Christian Hurtz, Mark E Robinson, Kadriye Nehir Cosgun, Markus Müschen

Blood (2023) 142 (Supplement 1): 2974.

https://doi.org/10.1182/blood-2023-190163

Published: 2023

Journal Articles

BCL6-Mediated Escape from Negative Selection Enables RAS-Driven B-Cell Transformation

Lai N. Chan, Christian Hurtz, Mark E. Robinson, Etienne Leveille, Huimin Geng, Rebecca Caeser, Liang Xu, Kohei Kume, Gang Xiao, Markus Müschen

Blood (2022) 140 (Supplement 1): 9177–9178.

https://doi.org/10.1182/blood-2022-169946

Published: 2022

Journal Articles

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

V. S. S. Abhinav Ayyadevara, Gerald Wertheim, John Chukinas, Joseph Patrick Loftus, Sung June Lee, Anil Kumar, Rahul S. Bhansali, Srividya Swaminathan, Thierry Besson, Junwei Shi, John D. Crispino, Sarah K Tasian, Martin P. Carroll, Christian Hurtz

Blood (2022) 140 (Supplement 1): 3486–3488.

https://doi.org/10.1182/blood-2022-162782

Published: 2022

Journal Articles

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Christian Hurtz, Gerald Wertheim, John Chukinas, Joseph Patrick Loftus, Sung June Lee, Anil Kumar, Rahul S. Bhansali, Srividya Swaminathan, Thierry Besson, Junwei Shi, John D. Crispino, Sarah K Tasian, Martin P. Carroll

Blood (2021) 138 (Supplement 1): 506.

https://doi.org/10.1182/blood-2021-144476

Published: 2021

Journal Articles

Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-Hlf B-ALL

Asen Bagashev, Joseph Patrick Loftus, Colin Wakefield, Gerald Wertheim, Christian Hurtz, Martin P. Carroll, Kimberly Stegmaier, Yana Pikman, Sarah K Tasian

Blood (2021) 138 (Supplement 1): 705.

https://doi.org/10.1182/blood-2021-148671

Published: 2021

Journal Articles

Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia

Lai N. Chan, Mark A. Murakami, Christian Hurtz, Kohei Kume, Jaewoong Lee, Kadriye Nehir Cosgun, Huimin Geng, Shai Izraeli, David M. Weinstock, Markus Müschen

Blood (2021) 138 (Supplement 1): 616.

https://doi.org/10.1182/blood-2021-149773

Published: 2021

Journal Articles

Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation

Lai N. Chan, Christian Hurtz, Etienne Leveille, Kohei Kume, Mark E. Robinson, Huimin Geng, Kadriye Nehir Cosgun, Markus Müschen

Blood (2021) 138 (Supplement 1): 792.

https://doi.org/10.1182/blood-2021-148653

Published: 2021

Journal Articles

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia

Caroline Duault, Anil Kumar, Adeleh Taghi Khani, Sung June Lee, Lu Yang, Min Huang, Christian Hurtz, Bryan Manning, Lucy Ghoda, Tinisha McDonald, Norman J. Lacayo, Kathleen M. Sakamoto, Martin Carroll, Sarah K. Tasian, Guido Marcucci, Jianhua Yu, Michael A. Caligiuri, Holden T. Maecker, Srividya Swaminathan

Blood (2021) 138 (16): 1465–1480.

https://doi.org/10.1182/blood.2020009871

Published: 2021

Includes: Supplemental data

Journal Articles

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Martin P. Carroll, MD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, MDPhD, Sung June Lee, BA, Anil Kumar, PhD, Anne Lehman, Joseph Patrick Loftus, BS, Grace Jeschke, PhD, John D. Crispino, PhD, Thierry Besson, PhD, Junwei Shi, PhD, Srividya Swaminathan, PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141258

Published: 2020

Journal Articles

Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia

Caroline Duault, PharmD, PhD, Anil Kumar, PhD, Adeleh Taghi Khani, PhD, Sung June Lee, BA, Lu Yang, PhD, Min Huang, PhD, Christian Hurtz, PhD, Bryan Manning, BS, Lucy Ghoda, PhD, Tinisha McDonald, BS, Norman J. Lacayo, MD, Kathleen M. Sakamoto, MD PhD, Martin P. Carroll, MD, Guido Marcucci, MD, Jianhua Yu, PhD, Michael A. Caligiuri, MD, Holden T. Maecker, PhD, Srividya Swaminathan, PhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-140044

Published: 2020

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

Rationale for Targeting BCL6 in MLL-Rearranged B-ALL

Lai N Chan, PhD, Christian Hurtz, PhD, Huimin Geng, PhD, Erica Ballabio, Gang Xiao, PhD, Gauri Deb, MS, PhD, Haytham Khoury, MD PhD, Scott A. Armstrong, MD PhD, Patricia Ernst, PhD, Ari Melnick, MD, Tom Arthur Milne, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 1239.

https://doi.org/10.1182/blood-2019-131565

Published: 2019

Journal Articles

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, Anne Lehman, Grace Jeschke, PhD, John D. Crispino, PhD MBA, Thierry Besson, PhD, Sarah K. Tasian, MD, Martin Carroll, MD

Blood (2019) 134 (Supplement_1): 2742.

https://doi.org/10.1182/blood-2019-123475

Published: 2019

Journal Articles

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Lai N Chan, PhD, Mark A. Murakami, MDMA,MMSc, Rebecca Caesar, Christian Hurtz, PhD, Kohei Kume, PhD, Teresa Sadras, PhD, Seyedmehdi Shojaee, PhD, Petri Pölönen, MSc, Amol Ugale, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Merja Heinäniemi, PhD, Olli Lohi, MD PhD, Arun P. Wiita, MD PhD, Shai Izraeli, MD, David M Weinstock, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3944.

https://doi.org/10.1182/blood-2019-130774

Published: 2019

Journal Articles

Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling

Lai N Chan, Christian Hurtz, PhD, Huimin Geng, PhD, Franziska Auer, PhD, Zhengshan Chen, MDPhD, Gang Xiao, PhD, Jae-Woong Lee, PhD, Kadriye Nehir Cosgun, PhD, B Hilda Ye, PhD, Markus Muschen, MD

Blood (2018) 132 (Supplement 1): 1336.

https://doi.org/10.1182/blood-2018-99-115514

Published: 2018

Journal Articles

Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia

Lai N Chan, Seyedmehdi Shojaee, PhD, Christian Hurtz, PhD, Franziska Auer, PhD, Zhengshan Chen, MDPhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Teresa Sadras, PhD, Deborah L White, PhD, Markus Muschen, MD

Blood (2018) 132 (Supplement 1): 568.

https://doi.org/10.1182/blood-2018-99-115536

Published: 2018

Journal Articles

Reciprocal Regulation of BCL6 and MLL Expression As a Vulnerability in MLL -Rearranged Acute Lymphoblastic Leukemia

Lai N Chan, Christian Hurtz, PhD, Huimin Geng, PhD, Cheryl L. Willman, MD, William L. Carroll, MD, Scott Armstrong, MD PhD, Thomas Arthur Milne, PhD BSc, MSc, Markus Muschen, MD

Blood (2017) 130 (Supplement 1): 1210.

https://doi.org/10.1182/blood.V130.Suppl_1.1210.1210

Published: 2017

Journal Articles

BCL6 Enables RAS-Driven Pre-B Cell Transformation in Acute Lymphoblastic Leukemia

Lai N Chan, Christian Hurtz, PhD, Rebecca Caesar, Seyedmehdi Shojaee, PhD, Gang Xiao, PhD, Huimin Geng, PhD, Mignon L. Loh, MD, B. Hilda Ye, PhD, Steven Kornblau, MD, Markus Muschen, MD

Blood (2017) 130 (Supplement 1): 1211.

https://doi.org/10.1182/blood.V130.Suppl_1.1211.1211

Published: 2017

NARROW

KMT2A -Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Targeting the SWI/SNF Chromatin Remodeling Complex Subunit SMARCA4 in ALL

Immunoglobulin Light Chains Control Permissiveness to Malignant B-Cell Transformation By RAS-Pathway Lesions

BCL6-Mediated Escape from Negative Selection Enables RAS-Driven B-Cell Transformation

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-Hlf B-ALL

Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia

Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Rationale for Targeting BCL6 in MLL-Rearranged B-ALL

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling

Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia

Reciprocal Regulation of BCL6 and MLL Expression As a Vulnerability in MLL -Rearranged Acute Lymphoblastic Leukemia

BCL6 Enables RAS-Driven Pre-B Cell Transformation in Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only